$CNTB

Connect Biopharma Holdings Ltd

Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California. It develops rademikibart, a human monoclonal antibody targeting IL-4Rα, for eosinophilic-driven respiratory diseases, with a focus on acute asthma and COPD exacerbations. The company is evaluating the drug in two Phase 2 trials and has completed a global Phase 2b trial in chronic asthma. It is not currently pursuing further development of rademikibart for atopic dermatitis. Connect retains rademikibart rights outside Greater China and has granted Simcere exclusive rights to develop, manufacture and commercialize it in Greater China. Simcere is responsible for development there, including an atopic dermatitis application and asthma. Connect relies on third-party contract manufacturers for materials and finished goods for preclinical studies and clinical trials. Under its Greater China agreement, Connect is eligible for milestone payments and royalties on sales.

2
0
4

No SEC Form 4 filings for $CNTB in the last 30 days.

See all $CNTB insider activity →
Med

Piper Sandler cuts Connect Biopharma stock price target on launch delay

Piper Sandler reduced its price target for Connect Biopharma (CNTB) to $5.00 from $7.00, citing a delayed launch timeline for rademikibart. The stock is trading at $0.64, down 74% over the past year. The company reported mixed Phase 2 trial results and plans to discuss Phase 3 programs with the FDA. Analysts have mixed price targets, ranging from $4 to $9.

CNTB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning CNTB (Connect Biopharma Holdings Ltd). Coverage has skewed bearish: 2 bullish, 0 neutral, and 4 bearish.

Recent CNTB coverage spans financial news, earnings and corporate actions.

What's driving CNTB

  • Analyst model delay and PT cut likely reinforce downside risk for CNTB until Phase 3 FDA alignment and timelines firm up.

    investing.com · Nov 17, 2026

  • Missed GAAP EPS and revenue likely pressures near-term sentiment and raises questions about cash burn versus operating runway.

    seekingalpha.com · Nov 17, 2026

  • Delisting risk and continued losses raise downside risk and can pressure liquidity and investor sentiment.

    quantisnow.com · Nov 16, 2026

  • Positive Phase 2 topline results and an FDA engagement plan increase the probability of advancing rademikibart into Phase 3, supporting risk-on sentiment for CNTB.

    SEC EDGAR 8-K · Nov 16, 2026

  • Positive early‑stage data may lift the stock as investors anticipate further FDA engagement and Phase 3 trials.

    tradingview.com · Nov 16, 2026

AlphAI scores every news story that mentions CNTB with an AI model for sentiment and relevance, and aggregates insider trades from Connect Biopharma Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CNTB

Score

CNTB: Connect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

Connect Biopharma (CNTB) filed an 8-K form, reporting a Q3 net loss of $16.2M ($0.26/share) and a 9-month loss of $52.8M. The company received a Nasdaq bid price deficiency notice for shares falling below $1.00 for 30 days.

$CNTBMedEarnings

Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update – Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and c

HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target

HC Wainwright & Co. reiterated a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying 641% upside from the last close. The firm cited positive clinical data for rademikibart, showing significant improvements in asthma and COPD treatments, and external validation from NEJM publication of tozorakimab data. Recent analyst price targets for the company range from $5 to $7.

$CNTBHighAI 8/10

BTIG cuts Connect Biopharma stock price target on trial timeline

BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.

$CNTBHighAI 9/10

Connect Biopharma stock jumps on positive COPD trial data

Connect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.

Related tickers